Alzheimer's disease clinical trials: contemplating trial outcomes, and adjusting for the future

In an expert view piece, Todd Feaster, clinical program manager for dementia with leading clinical trial technology and specialty services provider Bracket, employs his Alzheimer’s disease expertise to comment on the trial environment in this most challenging therapeutic area.

Alzheimer’s disease is deadly and difficult, and its impact is enormous. Understanding the scope of how the disease affects people is an ongoing challenge. In a recent report, voluntary health organization The Alzheimer’s Association showed that the number of patients suffering from the disease is expected to increase significantly over the next 30 years.

The 2016 report contains a comprehensive data set that illustrates the prevalence of Alzheimer’s, includes pertinent information on the caregivers who bear most of the burden of the disease, and describes both the cost of the disease to health care systems, but also how it can impact patients and their families directly.